Source comparison
BPC-157 50s Age Protocol Comparison
Acute soft tissue strain (hamstring, calf) 250–350mcg daily Subcutaneous near strain site 4–5 weeks Functional improvement weeks 2–3 Chronic tendinopathy (rotator cuff, Achilles) 400–500mcg daily Subcutaneous adjacent to tendon 6–8 weeks Noticeable improvement
This comparison does not assign a generated winner or score.
- Acute soft tissue strain (hamstring, calf)
- 250–350mcg daily
- Subcutaneous near strain site
- 4–5 weeks
- Functional improvement weeks 2–3
- Chronic tendinopathy (rotator cuff, Achilles)
- 400–500mcg daily
- Subcutaneous adjacent to tendon
- 6–8 weeks
- Noticeable improvement weeks 4–6
- Ligament sprain (knee, ankle)
- 350–450mcg daily
- Subcutaneous near ligament insertion
- 5–7 weeks
- Stability improvement weeks 3–5
- Joint cartilage degeneration (osteoarthritis)
- Intra-articular or peri-articular
- 8–12 weeks
- Symptom reduction weeks 6–8 (variable)
- Post-surgical recovery (tendon repair)
- 300–400mcg daily
- Subcutaneous near surgical site
- Reduced inflammation weeks 2–4
- Professional Assessment
- Higher doses (400–500mcg) and longer cycles (6–8 weeks) are standard in the BPC-157 50s age specific protocol due to slower baseline collagen turnover and higher prevalence of chronic vs acute injuries